Physician profile
Michael Martyn
NPI 1699113407
$89,361.37
in general payments reported to CMS, 2019-2025
14 companies · $50K in 2025
The $50K reported for 2025 was more than what 92% of Advanced Heart Failure and Transplant Cardiology providers received nationally (typical 2025 total: $1,046).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $174 · 2023: $994 · 2024: $38K · 2025: $50K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $79K · Travel and Lodging: $5,366 · Food and Beverage: $2,662 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,244 · Education: $39.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $78,876.25 |
| Travel and Lodging | $5,365.84 |
| Food and Beverage | $2,661.86 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,243.56 |
| Education | $39.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $38,461.78 | 2023-2025 | Farxiga, Wainua |
| Novo Nordisk As | $21,109.45 | 2024 | |
| Bridgebio Pharma, INC. | $16,196.81 | 2025 | Attruby |
| Bayer Healthcare Pharmaceuticals INC. | $7,968.55 | 2022-2025 | |
| Pfizer INC. | $3,171.18 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $775.25 | 2024 | Jardiance |
| Zoll Medical Corporation | $660.00 | 2023 | |
| Novo Nordisk INC | $401.07 | 2023-2025 | Ozempic, Wegovy |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $241.65 | 2022-2025 | Lifevest |
| Cvrx, INC. | $168.72 | 2025 | Barostim Neo System |
| Alnylam Pharmaceuticals INC. | $149.44 | 2025 | Onpattro |
| Merck Sharp & Dohme LLC | $39.62 | 2023 | Verquvo |
| Daxor Corporation | $17.85 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$4,123.33 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Martyn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.